Aktienanalyse zu USANA Health Sciences Inc (USNA)USNAUSANA Health Sciences Inc

USANA Health Sciences, Inc. and subsidiaries is a global nutrition, personal health and wellness company that develops and manufactures nutritional supplements, functional foods and personal care products. Its segments include Core nutritional and Hiya direct-to-consumer. The Core nutritional segment develops and manufactures science-based nutritional, personal care and skincare products with a primary focus on promoting long-term health and wellness in various geographic markets worldwide that are distributed through the core nutritional channel. The Hiya direct-to-consumer segment is a provider of children's health and wellness products in the United States that are distributed through the direct-to-consumer channel. Its product line includes USANA Nutritionals Optimizers, Essentials/CellSentials, Foods, Personal care and Skincare, and All other. USANA Nutritionals Optimizers products include Proflavanol, CoQuinone 30, and BiOmega-3. It operates in the Consumer Non-Cyclicals sector (MEDICINAL CHEMICALS & BOTANICAL PRODUCTS industry).

Currently, USANA Health Sciences Inc is not a strong buy. The stock is trading at $14.72, which is significantly below its 52-week high of $23.59, indicating a 37.5% decline from its peak. The company has reported a troubling net income of -$21.38 million in Q2 2026, which raises concerns about its profitability. Furthermore, the RSI of 58.13 suggests that the stock is nearing overbought territory, which could limit upside potential in the short term. While the forward P/E ratio of 8.08 indicates potential value, the recent earnings miss and declining sales trend are significant red flags. Therefore, investors should hold off on buying until there is clearer evidence of recovery and improved performance.

2 analysts cover USNA: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 39.00.